| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | 0.10 | -99 |
| Graham Formula | n/a |
ProPhotonix Limited (LSE: PPIX.L) is a US-based technology company specializing in advanced LED illumination solutions and laser modules. Operating in the Hardware, Equipment & Parts sector, the company serves diverse industries including machine vision, UV curing, biomedical, and industrial applications. ProPhotonix designs and manufactures high-performance LED systems such as the COBRA Cure FX series for UV curing and LED line lights for inspection. Additionally, it offers laser modules for alignment, dental, medical, and scientific uses, along with UVC LED systems for disinfection. Founded in 1951 and headquartered in Salem, New Hampshire, ProPhotonix has a global footprint, supplying products across North America, Europe, and Asia. The company’s innovative lighting and laser solutions cater to critical applications in 3D printing, defense, and industrial automation, positioning it as a key player in photonics and optoelectronics.
ProPhotonix presents a niche investment opportunity in the photonics and LED technology space, with a diversified product portfolio serving high-growth applications like UV curing and machine vision. The company reported revenue of £13.56 million and net income of £1.09 million in FY 2020, with strong operating cash flow of £2.14 million. Its debt is relatively low (£675k), and it holds £2.64 million in cash, suggesting financial stability. However, the company’s small market cap and negative beta (-0.26) indicate limited liquidity and potential volatility. The lack of dividends may deter income-focused investors, but growth-oriented investors might find value in its specialized technology and expanding industrial applications.
ProPhotonix competes in the highly specialized photonics and LED illumination market, where differentiation is driven by technological innovation and application-specific solutions. The company’s competitive advantage lies in its dual focus on LED systems and laser modules, allowing it to serve diverse industrial and medical markets. Its COBRA Cure FX series is a standout product in UV curing, competing against larger players with proprietary UV LED technology. However, ProPhotonix operates at a smaller scale compared to industry leaders, which may limit R&D spending and global distribution reach. The company’s strength in customized laser modules for OEM applications provides a defensible niche, but it faces pricing pressure from low-cost manufacturers in Asia. ProPhotonix’s ability to maintain profitability despite its size suggests efficient operations, but long-term growth depends on expanding its customer base and innovating in high-margin segments like UVC disinfection and structured light laser modules.